Monte Rosa Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

GLUE$10.50-0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

	Common stock
(in thousands, except share amounts)(unaudited)	Shares	Amount	Additionalpaid-incapital	Accumulatedothercomprehensive loss	Accumulateddeficit	TotalStockholders’equity
Balance—January 1, 2024	50,140,233	$5	$547,857	$(2,724)	$(365,888)	$179,250
Restricted common stock vesting	4,691	—	—	—	—	—
Exercise of common stock options	45,108	—	246	—	—	246
Provision for pension benefit obligation	—	—	—	35	—	35
Stock-based compensation expense	—	—	4,873	—	—	4,873
Unrealized loss on available-for-sale securities	—	—	—	(4)	—	(4)
Issuance of common stock pursuant to the at-the-market sales agreement	10,272	—	87	—	—	87
Net Loss	—	—	—	—	(31,968)	(31,968)
Balance—March 31, 2024	50,200,304	$5	$553,063	$(2,693)	$(397,856)	$152,519
Restricted common stock vesting	85,249	—	—	—	—	—
Exercise of common stock options	190,160	—	422	—	—	422
Provision for pension benefit obligation	—	—	—	35	—	35
Stock-based compensation expense	—	—	4,502	—	—	4,502
Unrealized loss on available-for-sale securities	—	—	—	(12)	—	(12)
Issuance of shares under employee stock purchase plan	93,859	—	298	—	—	298
Issuance of common stock pursuant to the at-the-market sales agreement, net of issuance costs of $89	120,234	—	797	—	—	797
Issuance of common stock pursuant to the Underwritten Public Offering, net of issuance costs of $3,290	10,638,476	1	46,709	—	—	46,710
Issuance of pre-funded warrant, net of issuance costs of $290	—	—	49,710	—	—	49,710
Net Loss	—	—	—	—	(30,310)	(30,310)
Balance—June 30, 2024	61,328,282	$6	$655,501	$(2,670)	$(428,166)	$224,671
Restricted common stock vesting	46,166	—	—	—	—	—
Exercise of common stock options	3,036	—	15	—	—	15
Provision for pension benefit obligation	—	—	—	37	—	37
Stock-based compensation expense	—	—	4,282	—	—	4,282
Unrealized gain on available-for-sale securities	—	—	—	311	—	311
Net Loss	—	—	—	—	(23,859)	(23,859)
Balance—September 30, 2024	61,377,484	$6	$659,798	$(2,322)	$(452,025)	$205,457

See accompanying notes to the condensed consolidated financial statements

Condensed consolidated statements of stockholders’ equity (unaudited) - Continued

	Common stock
(in thousands, except share amounts)(unaudited)	Shares	Amount	Additionalpaid-incapital	Accumulatedothercomprehensive loss	Accumulateddeficit	TotalStockholders’equity
Balance—January 1, 2023	49,323,531	$5	$503,696	$(1,752)	$(230,536)	$271,413
Restricted common stock vesting	33,192	—	—	—	—	—
Exercise of common stock options	4,261	—	18	—	—	18
Provision for pension benefit obligation	—	—	—	14	—	14
Stock-based compensation expense	—	—	3,974	—	—	3,974
Unrealized gain on available-for-sale securities	—	—	—	345	—	345
Net Loss	—	—	—	—	(32,038)	(32,038)
Balance—March 31, 2023	49,360,984	$5	$507,688	$(1,393)	$(262,574)	$243,726
Restricted common stock vesting	32,185	—	—	—	—	—
Exercise of common stock options	147,333	—	897	—	—	897
Provision for pension benefit obligation	—	—	—	14	—	14
Stock-based compensation expense	—	—	4,153	—	—	4,153
Unrealized loss on available-for-sale securities	—	—	—	(261)	—	(261)
Issuance of shares under employee stock purchase plan	51,977	—	303	—	—	303
Net Loss	—	—	—	—	(35,178)	(35,178)
Balance—June 30, 2023	49,592,479	$5	$513,041	$(1,640)	$(297,752)	$213,654
Restricted common stock vesting	75,287	—	—	—	—	—
Exercise of common stock options	397,914	—	1,101	—	—	1,101
Provision for pension benefit obligation	—	—	—	14	—	14
Stock-based compensation expense	—	—	4,468	—	—	4,468
Unrealized loss on available-for-sale securities	—	—	—	171	—	171
Net Loss	—	—	—	—	(34,884)	(34,884)
Balance—September 30, 2023	50,065,680	$5	$518,610	$(1,455)	$(332,636)	$184,524

See accompanying notes to the condensed consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.